231 related articles for article (PubMed ID: 34307165)
21. The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Sheng D; Lin F; Jiang P; Shi N
Front Pharmacol; 2023; 14():1157251. PubMed ID: 37305548
[No Abstract] [Full Text] [Related]
22. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.
Epstein RS; Aapro MS; Basu Roy UK; Salimi T; Krenitsky J; Leone-Perkins ML; Girman C; Schlusser C; Crawford J
Adv Ther; 2020 Aug; 37(8):3606-3618. PubMed ID: 32642965
[TBL] [Abstract][Full Text] [Related]
23. Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer.
Powell K; Prasad V
Transl Oncol; 2021 Nov; 14(11):101206. PubMed ID: 34419683
[TBL] [Abstract][Full Text] [Related]
24. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
25. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
27. Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis.
Dai HR; Yang Y; Wang CY; Chen YT; Cui YF; Li PJ; Chen J; Yang C; Jiao Z
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38760542
[TBL] [Abstract][Full Text] [Related]
28. Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics.
Li C; Preston RA; Dumas E; Beelen A; Marbury TC
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38639103
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.
Epstein RS; Nelms J; Moran D; Girman C; Huang H; Chioda M
Cancer Treat Res Commun; 2022; 31():100555. PubMed ID: 35421820
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer.
Li C; Rich B; Bullock JM; Barrière O; Marier JF; Beelen A
Br J Clin Pharmacol; 2023 Mar; 89(3):1067-1079. PubMed ID: 36180417
[TBL] [Abstract][Full Text] [Related]
31. Update 2021: Management of Small Cell Lung Cancer.
Tariq S; Kim SY; Monteiro de Oliveira Novaes J; Cheng H
Lung; 2021 Dec; 199(6):579-587. PubMed ID: 34757446
[TBL] [Abstract][Full Text] [Related]
32. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
Li C; Hart L; Owonikoko TK; Aljumaily R; Rocha Lima CM; Conkling PR; Webb RT; Jotte RM; Schuster S; Edenfield WJ; Smith DA; Sale M; Roberts PJ; Malik RK; Sorrentino JA
Cancer Chemother Pharmacol; 2021 May; 87(5):689-700. PubMed ID: 33595690
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.
Li C; Horton JK; Sale M; Curd L; Goti V; Tao W; Beelen A
Clin Drug Investig; 2022 Aug; 42(8):679-692. PubMed ID: 35842567
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
35. A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.
Balducci L; Falandry C; List A
Drugs Aging; 2023 Mar; 40(3):263-272. PubMed ID: 36715830
[TBL] [Abstract][Full Text] [Related]
36. New Drug Protects Against Myelosuppression Secondary to Lung Cancer Chemotherapy.
Aschenbrenner DS
Am J Nurs; 2021 Jun; 121(6):21. PubMed ID: 34009159
[TBL] [Abstract][Full Text] [Related]
37. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
38. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
Curr Oncol; 2019 Jun; 26(3):e372-e384. PubMed ID: 31285682
[TBL] [Abstract][Full Text] [Related]
39. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
Armstrong DK
Oncologist; 2004; 9(1):33-42. PubMed ID: 14755013
[TBL] [Abstract][Full Text] [Related]
40. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
